Navigation Links
Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit
Date:9/12/2007

CAMBRIDGE, Mass., Sept. 12 /PRNewswire/ -- Genstruct Inc., a biotechnology company translating the complexity of human biology to develop new successful therapeutics, announced today that its president and CEO, Dr. Keith O. Elliston, has been invited to speak at the Oncology Clinical Trial Summit in Arlington, Va., September 17-18.

Dr. Elliston will participate in a panel discussion focused on "Enhancing Development and Commercial Value Added in Care Delivery and Medicines by Leveraging and Integrating Innovative, Intelligent Technology Platforms." The panel will be moderated by Angeliki Kotsianti, M.D., Ph.D., director, Global Clinical Technology for Pfizer Human Health Technologies and be held on September 17 at 3:30 p.m.

"We understand the challenges of oncology clinical trials and have been focused on developing new approaches with our partnering pharmaceutical companies to deliver actionable hypotheses and mechanistic biomarkers for oncology drug development," said Dr. Keith O. Elliston, president and CEO at Genstruct. "Participating in this panel is a great opportunity to share our causal modeling methodology for translating research results into successful oncology clinical trials and to further improve healthcare delivery to cancer patients."

Dr. Elliston is an invited speaker at many biotechnology and pharmaceutical industry events. He is an experienced entrepreneur and intrapreneur who has dedicated his career to the development of leading-edge technology for drug discovery and drug development. Dr. Elliston spent over 10 years with Merck Research Laboratories, where he served as the Director of Bioinformatics, and the scientific director of the Merck Gene Index project. He then joined Bayer Pharmaceuticals where he founded their global genomics and bioinformatics efforts, and was the section head of Genomics and the worldwide head of Bioinformatics. In 1997 Dr. Elliston joined Gene Logic as Chief Scientific Officer and pioneered the development/application of molecular profiling to drug discovery. He was responsible for the development and management of six pharmaceutical research partnerships representing over $350 million in potential revenues. In 1999, Dr. Elliston founded Viaken Systems, where he was Chairman, President and CEO. He has been an advisor to Oak Investment Partners, Atlas Ventures, and other biotechnology venture capital groups, and has participated in the early stage development of a number of successful biotech companies. Dr. Elliston received an M.S. in genetics from the University of Minnesota, and a Ph.D. in molecular genetics from Rutgers University.

About Genstruct

Founded in 2002, Genstruct is a biotechnology company focused on elucidating the complexity of biology for the development of successful therapeutics. By modeling the components within the whole biological system, Genstruct delivers a deep molecular understanding of diseases and drug action, as well as mechanistic biomarkers to accelerate drug discovery and development programs. Genstruct engages in internal discovery and external development partnerships with top tier pharmaceutical companies, which apply systems biology in the areas of oncology, metabolic disorders, cardiovascular diseases and inflammation. The privately held company is based in Cambridge, Mass. For more information, please visit http://www.genstruct.com.

Genstruct and the Genstruct logo are registered trademarks and Molecular Epistemics, Knowledge Assembly, and Epistemics Engine are trademarks of Genstruct, Inc. All other trademarks or registered trademarks are properties of their respective owners.

Karen Higgins

A & E Communications for Genstruct

(610) 831-5723

khiggins@aandecomm.com


'/>"/>
SOURCE Genstruct, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Why companies dont get invited to the DEMO conference
2. Speaker announces business members of IT Task Force
3. Eight lawmakers named to Speakers IT task force
4. What do CIOs want? Fusion2007 speakers weigh in
5. Innovation expert speaks on the business-IT balancing act
6. Motorcycling entrepreneur to speak in Madison on success, failure, capital
7. Tommy Thompson will speak at World Congress on IT next May
8. Former NSF director to speak at UW-Madison
9. CIOs learn boardroom-speak
10. UW attracts speaker on network that could supplant Internet
11. DeLuca speaks out on entrepreneurialism, tech transfer, and WARF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), ... for operable and inoperable solid tumor cancers, announced today ... of NW Bio, will present at the Phacilitate Immunotherapy ... Hyatt Regency Hotel in Miami, Florida ... entitled "New Therapeutic Approaches – Expanding the Reach of ...
(Date:1/18/2017)... January 18, 2017 According to a new market research ... Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, Academic and Research Institutions) ... reach USD 739.9 Million by 2021 from USD 557.1 Million in 2016, growing ... ... MarketsandMarkets Logo ...
(Date:1/18/2017)... ... ... Executive search firm Slone Partners proudly supports the SCOPE ... of the clinical trials segment. Hosted in Miami, this conference brings together renowned ... , As executive talent specialists in the industries central to clinical trials, ...
(Date:1/18/2017)... ... 2017 , ... MYOLYN, which creates medical technology for people ... to the FDA, requesting clearance of the MyoCycle Home and the MyoCycle Pro ... , The submission marks a major milestone for the technology startup. MYOLYN spun ...
Breaking Biology Technology:
(Date:12/7/2016)... BioCatch , the global leader in behavioral biometrics, reported ... to over 40 granted and pending patents. ... , The Company,s IP portfolio ... System, Device, and Method Estimating Force Applied to a Touch Surface, ... hardware components needed to estimate the force and pressure applied to touch ...
(Date:12/7/2016)... 7, 2016   Veridium , a leader ... of new CEO James Stickland . Stickland, ... of experience, has served in senior executive roles ... specialized in expanding a pipeline of venture capital ... most recently served as managing director of U.K.-based ...
(Date:12/6/2016)... Dec. 6, 2016 Valencell , the leading ... has seen a third consecutive year of triple digit ... in 2016 with a 360 percent increase in companies ... increase was driven by sales of its wrist and ... in its technology for hearables for fitness and healthcare ...
Breaking Biology News(10 mins):